Lyell Immunopharma, Inc.

NASDAQ:LYEL

Biotechnology

Healthcare
$13.89 +1.20%

+$0.15 today

Market cap
$341.49M
Beta
-0.09
P/E (TTM)
-1.1
EPS (TTM)
-$11.26
52W Low $8.46High $45.00

Volume 0.11M

Average 0.09M

LYEL Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Lyell Immunopharma, Inc.NASDAQ: LYEL

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit turns negative

Q1 FY2026 gross profit was -$2.33M, compared with $7K a year earlier. Trailing-twelve-month gross profit was -$2.3M.

Context

  • Gross profit amounted to 31952.8% of revenue in FY2025, up 31852.8 pp from a year earlier.
  • Gross profit increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near -$2.33M or moves back toward the trailing-twelve-month quarterly average of -$575.25K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$2.33M-38933.3% QoQ
Last fiscal yearDec 2025
-$11.5M-18957.4% YoY
LTMMar 2026
-$2.3M-3640.0% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-33385.7%——
1 year-18957.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
(11.5M) USD
Year-over-year change
-18957.4%

Gross Profit vs competitors

How LYEL compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -3640.0% is the lowest of 7, against a peer median of +38.2%.
  • Gross profit amounts to 7422.6% of revenue for LYEL, versus a peer median of 66.4%.
LYEL Competitors
Gross Profit for LYEL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AMRNAmarin Corporation plcLTM Mar 2026$112.77M USD+52.6%-20.7%52.5%
ACIUAC Immune S.A.LTM Mar 2026CHF 3.7M CHF-86.9%-3.2%100.0%
EDITEditas Medicine, Inc.LTM Mar 2026$2.25M USD+105.3%+44.7%5.8%
SLNSilence Therapeutics plcLTM Mar 2026$612.12K USD—-62.8%66.4%
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$0 USD———
CABACabaletta Bio, Inc.LTM Mar 2026$0 USD———
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026-$66.6K USD———
GNLXGenelux CorporationLTM Mar 2026-$284K USD-39.2%—3550.0%
KYTXKyverna Therapeutics, Inc.LTM Mar 2026-$866K USD+97.1%——
LYELLyell Immunopharma, Inc.LTM Mar 2026-$2.3M USD-3640.0%—7422.6%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026-$77.25M USD+23.8%——
Peer median (excluding LYEL) —+38.2%-11.9%66.4%

Competitors are the stored peer set for LYEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.65M84.68M130K61K36K
Cost of Revenue000011.54M
Gross Profit10.65M84.68M130K61K(11.5M)
Gross Margin100.0%100.0%100.0%100.0%-31952.8%
Research & Development138.69M159.19M182.95M171.6M158.68M
Selling, General & Admin89.06M117.31M66.98M52.04M45.14M
Operating Expenses225.43M271.74M247.14M358.82M192.27M
Depreciation & Amortization13.62M18.02M20.25M19.63M11.54M
EBITDA(236.6M)(165.1M)(214.38M)(200.64M)(262.91M)
EBITDA Margin-2221.5%-195.0%-164909.2%-328923.0%-730302.8%
Operating Income(214.78M)(187.06M)(247.01M)(358.76M)(203.77M)
Operating Margin-2016.7%-220.9%-190006.2%-588123.0%-566038.9%
Interest Income1.17M7.05M23.45M24.07M13.08M
Interest Expense00000
Other Income / Expenses(35.44M)3.94M12.38M15.76M(70.67M)
Income Before Tax(250.22M)(183.12M)(234.63M)(342.99M)(274.45M)
Pre-Tax Margin-2349.5%-216.2%-180486.2%-562285.2%-762355.6%
Income Tax Expense00000
Net Income(250.22M)(183.12M)(234.63M)(342.99M)(274.45M)
Net Margin-2349.5%-216.2%-180486.2%-562285.2%-762355.6%
EPS (Basic)(1.03)(0.74)(0.93)(1.31)(16.06)
EPS (Diluted)(1.03)(0.74)(0.93)(1.31)(16.06)
Weighted Avg Shares12.14M12.35M12.55M13.07M17.09M
Weighted Avg Shares (Diluted)12.14M12.35M12.55M13.07M17.09M

Lyell Immunopharma, Inc.

NASDAQ:LYEL

Intrinsic Alpha fair value

Locked

Current Price

$13.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.